Adaptimmune Therapeutics plc Stock News

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

The biotech bear market has punished these two stocks too severely at this point.

Adaptimmune Therapeutics Plc - ADR (ADAP) shares closed 1.5% lower than its previous 52 week low, giving the company a market cap of $524M. The stock is currently down 10.4% year-to-date, down 42.3% over the past 12 months, and down 25.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 29.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 3.7% lower than its 5-day moving average, 11.8% lower than its 20-day moving average, and 28.6% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 41.0% The company's stock price performance over the past 12 months lags the peer average by 129.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attrac

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attrac

Wall Street analysts expect that Adaptimmune Therapeutics plc (NASDAQ:ADAP) will report earnings per share of $0.23 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Adaptimmune Therapeutics’ earnings. The highest EPS estimate is $0.71 and the lowest is ($0.26). Adaptimmune Therapeutics posted earnings of ($0.24) per share in […]

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has earned an average rating of Hold from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 []

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) have earned an average recommendation of Hold from the six analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. The average 12 []

Adaptimmune Therapeutics plc (NASDAQ:ADAP)s stock price rose 4.3% during trading on Friday . The company traded as high as $3.89 and last traded at $3.85. Approximately 3,653 shares traded hands during trading, a decline of 100% from the average daily volume of 1,197,290 shares. The stock had previously closed at $3.69. ADAP has been the []

Wall Street analysts expect Adaptimmune Therapeutics plc (NASDAQ:ADAP) to post earnings of $0.23 per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Adaptimmune Therapeutics earnings, with the highest EPS estimate coming in at $0.71 and the lowest estimate coming in at ($0.26). Adaptimmune Therapeutics reported earnings of ($0.24) []

These eight stocks could rebound nicely over the next year and beyond.

A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.

A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.